EntreMed, a US biotech with strong China connections, raised $10.7 million from two China-specific private equity funds: Kleiner Perkins Caufield Byers China Fund II LP and IDG-Accel China Growth Fund III LP. EntreMed will use the money to conduct clinical trials of its lead oncology drug candidate, ENMD-2076. In January, EntreMed filed an application with the SFDA to begin China trials of the drug in patients with triple-negative breast cancer. More details.... Stock Symbol: (NSDQ: ENMD) Share this with colleagues: // //